Scott Tozier
Analyst · Baird. You may begin
Thanks Luke and good morning everyone. In the first quarter, Albemarle generated unadjusted U.S. GAAP net income of $134 million. Net sales grew 6% and adjusted diluted EPS by 4%, excluding foreign exchange and divested businesses, compared to 2018. Adjusted diluted earnings per share was a $1.23 for the quarter, which is up $0.01 compared to 2018 pro forma results including the currency impact. Earnings growth in bromine and catalysts segments contributed about $0.10 and a lower share count contributed about $0.06. The gains were mostly offset by lithium, which was about $0.09 unfavorable and foreign exchange, which was about $0.04 unfavorable, driven primarily by the strength of the U.S. dollar. Corporate costs in the first quarter were $36 million, driven in part by negative currency expense and planned increases in professional services. We do not expect the first quarter spending rate to continue. Given first quarter costs and our updated view on the rest of the year, 2019 corporate costs are now expected to range from $120 million to $130 million. Net cash from operations was about $55 million, down from last year impacted by lower EBITDA, lower dividend payments from our joint ventures and higher cash taxes compared to the first quarter. Operating working capital ended the quarter just under 28% of sales, an increase from the fourth quarter of 2018, primarily due to increased inventory of spodumene in the lithium segment in preparation for the ramp of the Xinyu II expansion in China and increased inventory in catalysts in preparation for orders in the second half of the year. Capital expenditures during the first quarter were $216 million, on track with expectations. With the ramp of spending on Kemerton, continued buildout of La Negra and the early stages of the Salar yield improvement project, we continue to expect full year CapEx to range between $800 million and $900 million. Now let me move on to the business performance. Lithium ended the first quarter with sales of $292 million and adjusted EBITDA of $116 million. On a year-over-year basis, pricing was up 3%, benefiting from our long term agreement structure. Volume, however was down 3% versus prior year, primarily due to the impact of the rain events in the Salar. The adjusted EBITDA margin was solid at 40% and reflects the higher mix of carbonate sourced from toll manufacturers. Bromine specialties generated sales of almost $250 million and adjusted EBITDA of $79 million, up 10% and 12%, respectively, compared to the first quarter 2018. Adjusted EBITDA margin improved slightly year-on-year to about 32% as a result of higher sales prices and operating rates, partially offset by increased raw material prices. The increased volume was primarily driven by sales of clear brine fluids used for completion of offshore oil wells and sales of certain brominate derivatives used in the production of polymer resins. The market for flame retardants remained solid, particularly in electronics. First quarter catalyst sales of about $252 million increased by 8% compared to 2018, excluding divested businesses. Adjusted EBITDA was $60 million, up 5% from 2018. Growth was driven by our refining catalyst products, due to order timing of hydroprocessing catalysts and low single-digit price increases in fluid catalytic cracking or FCC catalysts, partially offset by a slight volume decline in FCC. Looking forward to the rest of the year. Lithium remains a volume story. Global demand remains in line with our expectations. As we discussed last quarter, we are starting to see some excess lithium carbonate in China coming from the nonintegrated spodumene converters. This is pulling short term carbonate pricing down. And for now, we have decided to forgo some opportunistic sales of total lithium carbonate in China until pricing improves. Our strategic customers in general continue to reflect healthy demand based on their current order pattern and continue to meet volume and pricing commitments under the terms of our long term agreements. Adding all this together, we now expect year-over-year volume growth of 15,000 to 20,000 metric tons and an adjusted EBITDA growth rate in the high teens. Note that we expect the second half to be notably stronger than the first due to the Xinyu production ramp and the brine improvements in Chile. Bromine had a strong start to the year and the current backlog of orders is healthy. With our improving outlook for the second half, we now expect full year bromine adjusted EBITDA growth in the mid to high single digits on a percentage basis. Our full year flat outlook on catalysts is unchanged. Shipments continue to be weighted to the second half with third quarter expected to be the strongest of the year. In rounding our commentary on our businesses, the fine chemistry services business, which is reported under the other segment, is beginning to show signs of recovery. We remain cautious. However, we believe this business now has the potential to deliver full-year adjusted EBITDA of around $25 million. For the total company, we are reaffirming the full year guidance. We expect pro forma net sales growth in the range of 9% to 15%. We expect overall corporate adjusted EBITDA margins of around 30%. And this would result in adjusted diluted earnings per share of between $6.10 and $6.50, a pro forma growth rate of 16% over 2018 at the midpoint. We expect the second quarter of 2018 to be about equal to the second quarter 2018 and the second half to be stronger than the first. As always, normal fluctuations in our business could have an impact on those quarterly results. I am excited about our progress in growing lithium capacity and earnings and the efforts of bromine and catalyst to generate increasing cash flow to fund that growth. These efforts, which are consistent with our strategy, continue to position us to benefit from the tremendous growth in the lithium market for decades to come. Now I will turn it back to back over to Dave.